Agenda for Day 2 - Tuesday 10 November, 2026
Location: Industry Voices Stage
The discussion will explore how the women’s health treatment landscape is shifting across several fronts — including scientific advances toward non-hormonal, targeted and potentially disease-modifying therapies; evolving regulatory and payer pathways; and changes in disease nomenclature and classification that better reflect underlying biology. The goal is to bring together scientific, clinical and regulatory perspectives to examine the latest signals and where the field is headed.
- Karen Chan - Senior Director, Lilly Gateway Labs, Eli Lilly and Company
- Kelle Moley - VP, Women's Health and Early Clinical Development, Eli Lilly and Company
- Anouk Petersen - Partner, McKinsey & Company
- Stasa Stankovic - Co-founder & CEO, OvartiX
- Stephane Thiroloix - CEO, Apikal Therapeutics
- Lea Wenger - CEO and Co-Founder, Cyclana Bio
Location: Industry Voices Stage
The EIC VentureMatch Pitching on Health Biotech spotlights 12 of the best health biotech companies backed by the European Innovation Council, working in therapeutics and advanced therapies, in technologies supporting research, development and clinical decision-making, and in adjacent health biotech fields. They have come through EIC evaluation, one of the most competitive selection processes in Europe, and hold EU grant funding, equity investment, or both. They will pitch to investors and pharma business development teams, followed by structured networking. If you would like to get involved or attend, please contact venturematch@bas.eic.eismea.eu.